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<Abstract>
Effect of orally active growth hormone secretagogue, MK-677, on somatic growth in rats
Junghun Lee
Department of Medicine
The Graduate School, Yonsei University
(Directed by Professor Ho-Seong Kim)
Growth hormone secretagogues (GHSs) have been considered as alternative for the treatment of
diseases related to growth hormone (GH) deficiency because of their ability to release GH in the body. 
As GH is a large peptide molecule, it must be injected into subcutaneous tissue or muscle to get it into 
the blood. However, some types of GHS can effectively stimulate GH release by administration 
through various routes such as intravenously, subcutaneously, intraperitoneally, and orally. The effects 
of MK-677, an orally active non-peptide mimic of GHS, on somatic growth were studied in rats. To 
confirm the GH stimulatory effect of MK-677, the concentration of serum GH was measured at
regular intervals after oral administration of 0, 2, or 4 mg MK-677/kg. To investigate the growth-
promoting effect of MK-677, body weight and body length were measured after oral administration of 
4mg MK-677/kg for 6 weeks. Blood samples were collected from the tail vein every 2 weeks for 
insulin-like growth factor-I determination. After decapitation, tibia length and epiphyseal plate width 
were measured, and the pituitary gland and hypothalamus were collected and frozen for analysis of 
GH, GH releasing hormone, GHS receptor, somatostatin, and somatostatin receptor mRNA by real-
time polymerase chain reaction. Oral administration of MK-677 at 4 mg/kg significantly increased 
peak GH concentrations by 1.8-fold, compared to baseline levels. However, oral administration of 
MK-677 at 4 mg/kg for 6 weeks did not increase the body length, body weight, width of tibia growth
plate, and serum level of insulin-like growth factor-I. At 6 weeks after treatment, the GH response to 
oral administration of MK-677 was abolished. Pituitary GH mRNA and hypothalamic GHRH mRNA
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levels did not differ between the control and 6-week treatment groups. Treatment with MK-677 did 
not alter pituitary and hypothalamic GHSR mRNA expression. Somatostatin mRNA expression in the 
hypothalamus was markedly increased in the treatment group compare to in controls. In addition, 
somatostatin receptor-2 mRNA expression in the pituitary gland was decreased in the treatment group 
compare to the controls.
Although oral administration of MK-677 stimulated GH secretion, prolonged administration for 6 
weeks attenuated the GH stimulatory effect of MK-677 and did not promote growth, which may be 
related to increased expression of somatostatin in the hypothalamus. Further studies are needed to
overcome the desensitization of growth hormone-releasing peptide after the prolonged clinical 
treatment of growth disorders. 
___________________________________________________________________________
Key words: growth hormone secretagogues, treatment outcome, growth hormone, somatostatin
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Junghun Lee
Department of Medicine
The Graduate School, Yonsei University
(Directed by Professor Ho-Seong Kim)
I. INTRODUCTION
Growth hormone secretagogues (GHSs) have been considered as an alternative to treat diseases 
related to growth hormone (GH) deficiency because of their ability to release GH in the body.1-3 
GHSs enhance the pulsatile release of GH in the anterior pituitary gland with resulting sustained 
elevation in insulin-like growth factor (IGF)-I levels. As GH is a large peptide molecule, it must be 
injected into subcutaneous tissue or muscle to get it into the blood. However, MK-677, an orally
active non-peptide mimic of GHSs, can stimulate the release of GH effectively by different ways such 
as intravenous, subcutaneous, intraperitoneal, and oral administration.4,5 Growth hormone-releasing 
peptide (GHRP)-6, which is a synthetic hexapeptide, also shows potent GH-releasing activity after 
intravenous, subcutaneous, intranasal and oral administration in humans. MK-677 is a non-peptide
spiropiperidine previously demonstrated to be functionally and mechanistically indistinguishable in 
vitro and in vivo from the potent peptide growth hormone secretagogue GHRP-6.1 MK-677 elevates
GH levels, as well as IGF-I and cortisol level in dogs after oral administration,6 and this stimulatory 
effect depends on the presence of an intact pituitary.7 Previous studies in humans demonstrated that 
daily oral administration of MK-677 in healthy elderly adults,8 GH-deficient adults9 for 4 weeks, and 
GH-deficient children10 for 7 days increased serum GH, IGF-I, and IGF binding protein (IGFBP)-3 
concentrations. Further, clinical trial studies of MK-677 have been conducted to improve body
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composition and metabolism in older adults11 or increase bone mass.12,13 However, the beneficial 
effect of MK-677 on growth promotion in children is controversial. The aims of this study were to 
investigate whether oral administration of MK-677 1) stimulates the secretion of serum GH and
increases the serum level of IGF-I, 2) enhances the body length and width of the growth plate in rats, 
and 3) influences the mRNA expression of GH, GH-releasing hormone (GHRH), GHS receptor, 
somatostatin, and somatostatin receptor in the pituitary and hypothalamus. 
I I. MATERIALS AND METHODS
1. Animals
The animals were allowed regular chow and water ad libitum, and were maintained at a temperature 
of 21 ± 2 ˚C and humidity of 60 ± 10% on 12-h light/dark cycles. Fermale Sprague-Dawley(SD) 
rats, approximately 4weeks of age,in each group were used for the experiment. The rats were fasted 
for 8 h before treatment and allowed water ad libitum. MK-677 was administered via a stomach tube, 
and blood samples were collected from the tail vein during the experiment, or from the heart after 
decapitation. Formulations of MK-677 were prepared at 1 mg/mL in distilled water. Distilled water 
was administered at 4 mL/kg as a placebo. All animal studies were approved by the Animal Care and 
Use Committee of the Yonsei University College of Medicine (No. 2013-0095). 
2. Experimental design
A. Dose range study
To determine whether oral administration of MK-677 can stimulate GH secretion in rats, MK-677 was 
administered at 0, 2, or 4 mg/kg via the stomach tube. Distilled water was administered at the same 
volume as a placebo. Blood samples were collected from the tail vein at 0, 30, 60, 90, and 120 min
after treatment. Plasma was harvested by centrifugation and stored in -70˚C for determination of GH.
The same experiment was conducted after oral administration of 4 mg/kg MK-677 to determine 
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whether the GH stimulatory effect was sustained after treatment with MK-677 for 6 weeks.
B. Efficacy of oral administration of MK-677 for 6 weeks
MK-677 was administered at 4 mg/kg via the stomach tube between 08:00- and 10:00 h for 6 weeks.
Distilled water was administered at 4 mL/kg as a placebo. To evaluate the growth-promoting effect of 
MK-677, body weight and body length were measured daily. The body length of rats was measured as 
the length from the nose to the anus. Blood samples were collected from the tail vein every 2 weeks 
for determination of IGF-I. The width of the tibia growth palate was measured after decapitation at 6 
weeks after treatment. Right tibia tissues were fixed in 4% paraformaldehyde for 24 h. Decalcification 
was performed with a EDTA-G solution (14.5 g EDTA, 1.25 g NaOH, and 15 mL glycerol dissolved 
in distilled water, pH 7.3. The solution was then brought to 100 mL and stored for 10–14 days at 4°C
as previously described. The fixed and decalcified tibia was embedded in paraffin and sectioned at 5 
µm. Paraffin bone sections were stained with hematoxylin and eosin (Sigma, St. Louis, MO, USA) 
according to the manufacturer's instructions.
C. Effect of MK-677 on expression of GH, GHRH, GHS receptor (GHSR), somatostatin, and 
somatostatin receptor mRNA in pituitary gland and hypothalamus
To determine whether MK-677 can alter GH, GHRH, GHSR, somatostatin, and somatostatin receptor 
mRNA expression, rats were sacrificed by decapitation at 6 weeks after treatment. The pituitary gland 
and hypothalamus were collected and frozen for analysis of GH, GHRH, GHSR, somatostatin, and 
somatostatin receptor mRNA by real-time polymerase chain reaction (RT-PCR). 
3. Hormone analyses 
All hormone analyses were performed by enzyme-linked immunosorbent assay (ELISA). GH was 
determined by ELISA(Elabscience Biotech, Wuhan, China) with a sensitivity of 0.188 ng/mL, intra-
assay coefficient of variation of 3.87 - 5.15%, and inter-assay coefficient of variation of 7.04 - 8.45%. 
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IGF-1 was determined by ELISA (Elabscience Biotech, Wuhan, China) with a sensitivity of 
18.75 pg/mL, intra-assay coefficient of variation of 3.4 - 5.7%, and inter-assay coefficient of variation 
of 5.7 - 7.9%.
4. RT-PCR analysis 
Total RNA was isolated from the cells using the Trizol reagent (Invitrogen, Carlsbad, CA, USA). Five 
micrograms of total RNA was subjected to reverse transcription using the Superscript TM III first-
strand synthesis system (Invitrogen) according to the manufacturer’s instructions. Real-time PCR was 
conducted in 20 µL of reaction mixtures containing cDNA, Taqman primer pairs, and Taqman 
universal PCR master mix (Applied Biosystems, Foster City, CA, USA). The primer pairs were 
obtained from Applied Biosystems (Rn01495894 for GH, Rn00580832 for GHRH, Rn00821417 for 
GHSR, Rn00561967 for somatostatin, Rn01464950 for somatostatin receptor-2, Rn02535169 for 
somatostatin receptor-5, Rn01775763 for GAPDH). Amplification was performed in duplicate with 
the ABI 7300 system (Applied Biosystems) with the following profile: 50°C for 2 min, 95°Cfor 10 
min, and 40 cycles of 95°C for 15 s and 60°C for 1 min. The gene expression in each sample was 
expressed in terms of the threshold cycle (Ct) normalized to GAPDH (ΔCt). The ΔCt values were 
compared between samples from MK-677 treated tissues (hypothalamus and pituitary gland)and 
control samples, to calculate ΔΔCt. The final comparison of the transcript ratios between samples is 
given as 2 –ΔΔCt.14
5. Statistical analyses 
All statistical calculations were performed using SAS version 9.2 (SAS Institute Inc., Cary, NC, USA). 
Two-tailed t test was used to test for differences between the treatment group and controls. P-values 
<0 .05 were considered statistically significant. 
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III. RESULTS
1. GH response to MK-677 at baseline and 6 weeks after treatment
Serum GH concentrations after oral administration of 2 and 4 mg/kg of MK-677 or placebo at 
baseline are shown in Fig.1A. Oral administration of MK-677 at 4 mg/kg significantly increased GH 
concentrations with a 1.8-fold increase in peak GH concentration (45.7 ng/mL), whereas 
administration of distilled water did not increase GH concentrations. The GH area under the curve 
(AUC) showed a similar significant increase after administration of 4 mg/kg of MK-677 compared to 
the distilled water control group (1090±00 vs. 206±00 ng/min/mL, P<0.05). The peak GH 
concentration was observed at 60 min after treatment and returned to near-pretreatment levels by 120 
min. The increased response of GH after administration of MK-677 was abolished in animals treated 
with MK-677 for 6 weeks. Oral administration of MK-677 at 4 mg/kg in rats treated with MK-677 for 
6 weeks did not increase the GH concentrations (Figure 1B). 
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Figure 1.Serum GH levels after oral administration of MK-677. (A) Dose range study at baseline. 
MK-677 at 0, 2, and 4 mg/kg were administered. (B) MK-677 at 4 mg/kg was administered in rats 
after treatment of MK-677 for 6 weeks. n=4/treatment.*** P<0.001.
2. Efficacy of oral administration of MK-677 for 6 weeks
The treatment group showed no increase in body weight, body length, and width of the tibia growth 
plate at 6 weeks of MK-677 treatment, compared to the control group (Figure 2 A, B, C). Serum IGF-I 
levels at 2, 4, and 6 weeks were not changed compared to the level at baseline, and did not differ 
between the treatment group and control group at each time point (Figure 3). 
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Figure 2.Efficacy of oral administration of MK-677 for 6 weeks.(A) Body weight, (B) body length, 
and (C) width of tibia growth plate. n=4/treatment.
Figure 3.Serum IGF-I levels after oral administration of MK-677. n=4/treatment.
3. Effect of MK-677 on expression of GH, GHRH, GHSR, somatostatin, andsomatostatin receptor 
mRNA in pituitary gland and hypothalamus
Pituitary GH and hypothalamic GHRH mRNA levels did not differ between the control and treatment 
groups (Figure 4 A, B). Pituitary and hypothalamic GHSR mRNA expression did not differ between 
the control and treatment groups (Figure 4 C). Somatostatin mRNA expression in  the
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hypothalamus was markedly increased in the treatment group compare to in the control group (Figure 
4 D). In addition, somatostatin receptor-2 mRNA expression in the pituitary gland was decreased in
the treatment group compare to in the control group (Figure 4 E).
Figure 4. Effect of MK-677 on expression of GH, GHRH, GHS receptor (GHSR), somatostatin 
(SST), somatostatin receptor-2 (SSTR-2) and somatostatin receptor-5 (SSTR-5) mRNA in 
hypothalamus or pituitary gland. (A) Pituitary GH mRNA level, (B) hypothalamic GHRH mRNA 
level, (C) hypothalamic and pituitary GHSR mRNA level, (D) hypothalamic somatostatin mRNA 
level, (E) pituitary somatostatin receptor-2 mRNA level, (F) Pituitary somatostatin receptor-5 mRNA 
level. n=4/treatment.** P <0.01, *** P <0.001.
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I V. DISCUSSION
Secretion of GH in the pituitary gland is regulated by GHRH and somatostatin in the hypothalamus. 
GHRH stimulates the release of GH through the GHRH receptor, whereas somatostatin represses the 
release of GH through the somatostatin receptor.15 In 1977, new synthetic peptides, with GH-releasing 
ability, were discovered.16 These new compounds are enkephalin analogs, which have weak GH-
releasing activity in vitro and are inactive in vivo. Subsequently, additional more potent GHRPs were 
developed by chemical modifications.17 GHRPs have no sequential homology with GHRH and are 
more effective for inducing GH release even at the same dose of GHRH.18 Many studies found that 
GHRPs have GH releasing activity in several species via their own receptors known as the GHS 
receptor, not the GHRH receptor.19 GHRPs have several effective routes by intravenous, subcutaneous, 
intranasal and oral administration. Recently, to overcome the limit of low oral bioavailability, peptide-
mimicking and non-peptidyl GHS, which can be administered orally, were developed. 4,5,20 SM-
130686, an orally active non-peptidyl GHS, was developed and was confirmed to have GH-releasing 
activity. In rats, SM-130686 enhanced GH secretion and body weight gain.20 Another non-peptidyl 
GHS, ibutamorenmesylate (MK-677), was reported to stimulate the release of GH, and showed an 
oral bioavailability of more than 60%.4,18 Oral administration of MK-677 also elevates GH level, as 
well as IGF-I and cortisol level in dogs,6and this stimulatory effect is dependent on the presence of an 
intact pituitary.7 In humans, daily oral administration of MK-677 in healthy elderly adults,8GH-
deficient adults,9 or GH-deficient children10 increases serum GH, IGF-I, and IGFBP-3 concentrations, 
suggesting that these GHSs are potential treatments for growth disorders. However, repeated 
administration of GHRP has been reported to desensitize the stimulatory effect on GH secretion and 
there have been no studies of the growth promoting effect after long-term use, limiting clinical 
application.21
In our study, oral administration of 4 mg/kg of MK-677 increased the peak concentrations of serum 
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GH by 1.8-fold compared to basal level and GH AUC was significantly increased, suggesting that 
oral administration of MK-677 has GH-releasing activity. However, the growth promoting effect 
assessed by measuring the body weight, body length, width of tibia growth plate, and serum level of 
IGF-I was not observed after oral administration of 4 mg/kg of MK-677 for 6 weeks. The 
desensitization phenomenon of GHRP has been reported previously.22-26 In an animal study using 
transgenic growth-retarded rats, infusion of GHRP-6 for 7 days produced a dose-dependent increase 
in body weight gain, and accelerated of skeletal growth.26 However, this growth promoting effect was 
observed only in the group infused with GHRP-6 at 3-h pulses. Continuous infusion of GHRP-6 was 
only effective in accelerating growth for the first 2 days of infusion, suggesting that the growth 
response with continuous infusion is transient because of desensitization. In normal female rats, 
continuous infusion of GHRP has been reported to induce tachyphlaxis after an initial increase in 
growth velocity, suggesting that continuous infusion of GHRP induce desensitization.27 Repeated 
administration of hexarelin at 120-min intervals decreased the magnitude of the GH response in 
healthy adult males.25 In our study, oral administration of MK-677 did not stimulate GH secretion 
after treatment for 6 weeks, suggesting that the initial GH stimulatory effect of MK-677 was abolished 
in animals treated with MK-677 for 6 weeks. 
The mechanisms of GHRP desensitization after continuous infusion or long-term use have not been
fully clarified. Many studies demonstrated that continuous infusion of GHRP did not alter GH stores 
and GHRH receptor expression in the pituitary gland, or GHRH expression in the hypothalamus.22,23,26
The most direct and probable mechanism is the down regulation of GHSR in the pituitary gland and 
hypothalamus after treatment with GHRP. However, previous studies demonstrated that continuous 
infusion of GHRP-6 did not alter hypothalamic GHSR expression in arcuate and ventromedial 
nuclei,28 or even increase arcuate GHSR expression.26 The results of this study also showed that oral 
administration of MK-677 for 6 weeks did not alter pituitary GH mRNA and hypothalamic GHRH 
mRNA expression, or GHSR mRNA expression in the pituitary gland and hypothalamus. Another 
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possible mechanism of desensitization induction is increased expression of somatostatin in the 
periventricular nucleus following continuous infusion of GHRP.26, 29 In our study, somatostatin mRNA 
expression in the hypothalamus was markedly increased after treatment with MK-677 for 6 weeks, 
which inhibits GHRH- and GHS-induced GH secretion. In contrast, somatostatin receptor-2 mRNA 
expression in the pituitary gland was decreased, which may have resulted from elevated expression of 
somatostatin in the hypothalamus. Elevated somatostatin expression was reported to inhibit 
corticotropin releasing factor-induced ACTH secretion.30 Moreover, GHRP activates the 
hypothalamo-pituitary-adrenal axis, 31 and elevated glucocorticoids interact with the GH control. 
Continuous infusion of GHRP-6 suppresses the corticosterone response to bolus injection of GHRP-
6.26 Additional studies investigating the effects of GHRP on hypothalamo-pituitary-adrenal axis, and 
its interaction with the GH axis, are necessary.
V. CONCLUSION
In conclusion, oral administration of GHS, MK-677 stimulates GH secretion. However, prolonged 
oral administration for 6 weeks did not promote growth and abolished the GH stimulatory effect of 
MK-677, which may have resulted from increased expression of somatostatin in the hypothalamus. 
Further studies are needed to develop a strategy for overcoming the increased expression of 
somatostatin, thereby leading to growth promotion. 
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ABSTRACT(IN KOREAN)
성장호르몬 분비촉진제 경구투여에 의한 흰쥐에서의 신체성장 효과
<지도교수 김호성>
연세대학교 대학원 의학과
이정헌
성장호르몬 분비촉진제 (growth hormone secretagogues,GHS)는 성장호르몬 분비를 자극
하는 효과를 보이므로 성장장애 치료를 위한 대안으로 여겨진다. 성장호르몬은 크기가
큰 펩티드 분자이기에 이는 피하주사 혹은 근육주사로 투여 해야 한다. 하지만 성장호르
몬 분비촉진제(growth hormone secretagogues,GHS)는 피하주사, 근육주사, 복강주사 혹
은 경구투여로 성장호르몬분비를 촉진 시킬 수 있다. 성장호르몬 분비촉진제 MK-677 의
신체성장 효과를 흰쥐를 통하여 조사하였다. 성장호르몬 분비촉진제, MK-677 4 mg/kg를
경구로 투여하였을 때 성장호르몬 분비가 최대 1.5배 증가하는 것을 확인하였다. 그러나
6주 동안 흰쥐에 4mg/kg의 MK-677와 위약을 경구 투여하였을 때 신장, 체중, 정강이뼈
길이 모두 큰 차이가 없었으며,인슐린양 성장인자-I (insulin-like growth factor I, 
IGF-I)의 농도에도 차이가 없었다. 6주 동안 MK-677을 투여한 후에는 MK-677의 성장호르
몬 분비 자극 효과가 소실되었다. MK-677을 6주 동안 투여한 후에는 뇌하수체의 성장호
르몬 mRNA, 시상하부의 성장호르몬방출호르몬 mRNA와 뇌하수체와 시상하부의 성장호르몬
분비촉진제 수용체 mRNA 발현에는 영향을 주지 않았으나, 시상하부의 소마토스타틴 mRNA 
발현이 증가되었다.성장호르몬 분비촉진제가 성장장애의 치료에 이용되기 위해서는 장기
간 투여 시 나타나는 소미토스타틴 발현의 증가를 조절하는 방안에 대한 연구가 필요하
리라 사료된다. 
___________________________________________________________________________
핵심되는말:성장호르몬 분비촉진제, 치료 효과, 성장호르몬, 소마토스타틴
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